Schering-Plough (SGP)
Biotechnology firm Codexis says it has reached an important development milestone in its effort to design a biocatalytic process to produce a key intermediate for a Schering-Plough drug (SGP), reducing manufacturing costs and environmental waste. This platform technology can create new intellectual property opportunities, which can help extend the lifetime of drug products. Look to see a positive push in SGP in the upcoming weeks.
posted by Stock Administrator @ 2:39 AM
Schering-Plough (SGP)
Biotechnology firm Codexis says it has reached an important development milestone in its effort to design a biocatalytic process to produce a key intermediate for a Schering-Plough drug (SGP), reducing manufacturing costs and environmental waste. This platform technology can create new intellectual property opportunities, which can help extend the lifetime of drug products. Look to see a positive push in SGP in the upcoming weeks.
posted by Stock Administrator @ 2:39 AM
0 Comments:
Post a Comment
<< Home